PURPOSE:Polyvinyl alcohol (PVA) is a successful tear film stabiliser and is widely used in comfort drops and some soft contact lens materials. A PVA-containing lens, nelfilcon A has been modified to include additional (non-functional) PVA in order to provide improved comfort. This study aims to examine the clinical performance of this nelfilcon A lens with AquaRelease (AquaRelease). METHODS: Two contralateral, investigator masked, open label, subjective and objective evaluations were conducted. The first examined the effect of adding increased molecular weight PVA to nelfilcon A (n=5), and the second compared this AquaRelease lens to ocufilcon B (n=34). The principal measures were non-invasive break-up time (NIBUT) and subjective comfort, which were assessed at the beginning and end of a week of daily wear, and three times throughout 1 day at 8, 12 and 16 h. RESULTS: All subjects successfully completed the daily wearing schedule of 16h. On initial insertion, subjective comfort and NIBUT improved for AquaRelease than original nelfilcon A lenses (p<0.05). Initial comfort was better for AquaRelease compared to ocufilcon B lenses (p=0.01); however, NIBUT was not statistically different (11.7+/-15.6s versus 8.4+/-6.8s; p=0.26). Subjective comfort decreased with time (p<0.001), but there was no significant difference between AquaRelease and ocufilcon B lenses (p=0.16). NIBUT was not significantly affected by time (p=0.56) or between lenses (p=0.33). At the end of a weeks' wear, subjective initial, end-of-day, overall comfort and vision were rated significantly better with AquaRelease than ocufilcon B (p<0.01). CONCLUSIONS: Release of additional non-functionalised PVA from the nelfilcon A lenses appears to enhance comfortable contact lens wear.
RCT Entities:
PURPOSE:Polyvinyl alcohol (PVA) is a successful tear film stabiliser and is widely used in comfort drops and some soft contact lens materials. A PVA-containing lens, nelfilcon A has been modified to include additional (non-functional) PVA in order to provide improved comfort. This study aims to examine the clinical performance of this nelfilcon A lens with AquaRelease (AquaRelease). METHODS: Two contralateral, investigator masked, open label, subjective and objective evaluations were conducted. The first examined the effect of adding increased molecular weight PVA to nelfilcon A (n=5), and the second compared this AquaRelease lens to ocufilcon B (n=34). The principal measures were non-invasive break-up time (NIBUT) and subjective comfort, which were assessed at the beginning and end of a week of daily wear, and three times throughout 1 day at 8, 12 and 16 h. RESULTS: All subjects successfully completed the daily wearing schedule of 16h. On initial insertion, subjective comfort and NIBUT improved for AquaRelease than original nelfilcon A lenses (p<0.05). Initial comfort was better for AquaRelease compared to ocufilcon B lenses (p=0.01); however, NIBUT was not statistically different (11.7+/-15.6s versus 8.4+/-6.8s; p=0.26). Subjective comfort decreased with time (p<0.001), but there was no significant difference between AquaRelease and ocufilcon B lenses (p=0.16). NIBUT was not significantly affected by time (p=0.56) or between lenses (p=0.33). At the end of a weeks' wear, subjective initial, end-of-day, overall comfort and vision were rated significantly better with AquaRelease than ocufilcon B (p<0.01). CONCLUSIONS: Release of additional non-functionalised PVA from the nelfilcon A lenses appears to enhance comfortable contact lens wear.
Authors: Fiona Stapleton; Carl Marfurt; Blanka Golebiowski; Mark Rosenblatt; David Bereiter; Carolyn Begley; Darlene Dartt; Juana Gallar; Carlos Belmonte; Pedram Hamrah; Mark Willcox Journal: Invest Ophthalmol Vis Sci Date: 2013-10-18 Impact factor: 4.799
Authors: Chau-Minh Phan; Hendrik Walther; Donald Riederer; Charis Lau; Kathrine Osborn Lorenz; Lakshman Nagapatnam Subbaraman; Lyndon Jones Journal: J Biomed Mater Res B Appl Biomater Date: 2018-10-16 Impact factor: 3.368
Authors: Essam A Tawfik; Mariagiovanna Scarpa; Hend E Abdelhakim; Haitham A Bukhary; Duncan Q M Craig; Susan A Barker; Mine Orlu Journal: Pharmaceutics Date: 2021-01-19 Impact factor: 6.321